Olanzapine

奥氮平

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameOlanzapine
Drug Alias Nameolanzapine奥兰扎平奥兰氮平olanzapinum双羟萘酸奥氮平 +[28] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D1 receptor antagonistsDopamine D2 receptor antagonistsSerotonin 2 (5-HT2) receptor antagonists
TargetsDopamine D1 receptorDopamine D2 receptorSerotonin 2 (5-HT2) receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingBipolar II DisorderBipolar I Disorder +[37] 
Global Approved IndicationsSchizophreniaBipolar Disorder
Approved Indications in ChinaSchizophreniaBipolar Disorder
Original Approved Country/TerritoryEU
Original Approved Date1996/09/27
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesAmani Hassan Abdel-WahabAugusta UniversityUniversity of Sao Paulo +[25] 
Inactive CompaniesImpel PharmaceuticalsDrexel UniversityMylan Pharmaceuticals Inc +[15] 
Active IndicationsChemotherapy-induced nausea and vomitingSolid tumoursSchizophrenia +[27] 
Inactive IndicationsBipolar II DisorderBipolar I DisorderBorderline Personality Disorder +[10] 

Other Information

ATC CodeN05AH03
Related LinksWikipediaDrugBankKEGG